These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. CD3-positive plasmablastic B-cell neoplasms: a diagnostic pitfall. Pan Z; Chen M; Zhang Q; Wang E; Yin L; Xu Y; Huang Q; Yuan Y; Zhang X; Zheng G; Yuan J Mod Pathol; 2018 May; 31(5):718-731. PubMed ID: 29327711 [TBL] [Abstract][Full Text] [Related]
3. Plasmablastic lymphoma with aberrant expression of CD3 and CD4. Yan J; Sakhdari A Int J Lab Hematol; 2022 Aug; 44(4):692-693. PubMed ID: 35060329 [No Abstract] [Full Text] [Related]
4. Vulvar and gastric involvement in plasmablastic lymphoma. Galvão Ferreira PA; Gomes Luna C; Silva MF; Soares LC; Pinho de Oliveira MA Eur J Gynaecol Oncol; 2017; 38(2):308-310. PubMed ID: 29953802 [TBL] [Abstract][Full Text] [Related]
5. CD3-positive plasmablastic lymphoma reported in two cases: A potential diagnostic caveat. Wong YP; Masir N; Chew MX Indian J Pathol Microbiol; 2021; 64(3):579-583. PubMed ID: 34341278 [TBL] [Abstract][Full Text] [Related]
6. Papuloerythroderma of Ofuji associated with an indolent CD3(-), CD4(+), TCR(-) peripheral T-cell lymphoma. Kim S; Jahan-Tigh R; Duvic M Leuk Lymphoma; 2013 Sep; 54(9):2059-61. PubMed ID: 23294328 [No Abstract] [Full Text] [Related]
7. CD3- and CD4-positive plasmablastic lymphoma: a literature review of Japanese plasmablastic lymphoma cases. Suzuki Y; Yoshida T; Nakamura N; Kamata H; Kotani S; Ohsaka M; Kajita S; Miyazaki K; Ohtani S; Nakayama M; Horie R; Hayakawa K; Niitsu N; Higashihara M Intern Med; 2010; 49(16):1801-5. PubMed ID: 20720363 [TBL] [Abstract][Full Text] [Related]
8. Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma. Carras S; Regny C; Peoc'h M; Gervasoni J; Gressin R; Cahn JY; Molina L Leuk Lymphoma; 2015; 56(10):2986-8. PubMed ID: 25676034 [No Abstract] [Full Text] [Related]
9. Plasmablastic transformation of plasma cell myeloma with heterotropic expression of CD3 and CD4: a case report. Mishra P; Kakri S; Gujral S Acta Clin Belg; 2017 Aug; 72(4):250-253. PubMed ID: 27374484 [TBL] [Abstract][Full Text] [Related]
10. Cutaneous localization of plasmablastic multiple myeloma with heterotopic expression of CD3 and CD4: Skin involvement revealing systemic disease. Varricchio S; Pagliuca F; Travaglino A; Gallo L; Villa MR; Mascolo M J Cutan Pathol; 2019 Aug; 46(8):619-622. PubMed ID: 31025408 [TBL] [Abstract][Full Text] [Related]
11. Immunoelectron microscopy in mycosis fungoides and benign dermatoses. Expression of CD3, CD4 and CD7 receptors. Grzanka AA; Placek W; Grzanka A; Sokolowska-Wojdylo M; Zuryn A Neoplasma; 2010; 57(1):41-6. PubMed ID: 19895171 [TBL] [Abstract][Full Text] [Related]
12. The hypereosinophilic syndrome associated with CD4+CD3- helper type 2 (Th2) lymphocytes. Bank I; Amariglio N; Reshef A; Hardan I; Confino Y; Trau H; Shtrasburg S; Langevitz P; Monselise Y; Shalit M; Rechavi G Leuk Lymphoma; 2001 Jun; 42(1-2):123-33. PubMed ID: 11699199 [TBL] [Abstract][Full Text] [Related]
13. Daily quality control in CD3+ and CD4+ T cell estimation by the FACSCount system at a tertiary care center in south India. Ramalingam VV; Mani M; Sundaresan VC; Karunaiya RJ; Sachithanandham J; Kannangai R Clin Vaccine Immunol; 2012 Oct; 19(10):1693-6. PubMed ID: 22855396 [TBL] [Abstract][Full Text] [Related]
14. Circulating CD4+ T lymphocytes with intracellular but no surface CD3 antigen in five of seven patients consecutively diagnosed with angioimmunoblastic T-cell lymphoma. Serke S; van Lessen A; Hummel M; Szczepek A; Huhn D; Stein H Cytometry; 2000 Jun; 42(3):180-7. PubMed ID: 10861691 [TBL] [Abstract][Full Text] [Related]
15. Malignant ulcer: a great mimicker of gastric plasmablastic lymphoma. Johan S; Khairuddin A; Zuki AM; Teng WW; Hayati F; Mra A; Azizan N Clin J Gastroenterol; 2021 Aug; 14(4):1027-1030. PubMed ID: 33797037 [TBL] [Abstract][Full Text] [Related]
16. Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review. Mori H; Fukatsu M; Ohkawara H; Oka Y; Kataoka Y; Taito S; Ikezoe T Int J Hematol; 2021 Dec; 114(6):639-652. PubMed ID: 34462886 [TBL] [Abstract][Full Text] [Related]
17. Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells. Hilchey SP; De A; Rimsza LM; Bankert RB; Bernstein SH J Immunol; 2007 Apr; 178(7):4051-61. PubMed ID: 17371959 [TBL] [Abstract][Full Text] [Related]
18. Clinical field site evaluation of the FACSCount for absolute CD3+, CD3+ CD4+, and CD3+ CD8+ cell count determinations in Thailand. Young NL; Ponglertnapakorn P; Shaffer N; Srisak K; Chaowanachan T; On-Thern V; Kittinunvorakoon C; Bunwattanakul A; Suksaweang S; Pobkeeree V; Punnotok J; Mastro TD Clin Diagn Lab Immunol; 1997 Nov; 4(6):783-6. PubMed ID: 9384308 [TBL] [Abstract][Full Text] [Related]
19. Bone marrow infiltration by plasmablastic neoplasm: plasmablastic myeloma or plasmablastic lymphoma? Eladl E; Chang H Blood; 2021 Mar; 137(9):1268. PubMed ID: 33661296 [No Abstract] [Full Text] [Related]
20. Defective TCR surface expression associated with impaired TCR beta-chain assembly in a patient with cutaneous T-cell lymphoma. Fischer MB; Hauber I; Födinger M; Wolf HM; Thon V; Donath P; Eibl MM; Knobler RM J Invest Dermatol; 1995 Apr; 104(4):537-40. PubMed ID: 7706773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]